FRIDAY, SEPTEMBER 30, 2016

Meridian signs agreement to provide illumigene testing to Premier health facilities

Meridian Bioscience recently penned an agreement to allow North Carolina-based Premier health facilities to use illumigene rapid tests to screen for C. difficile, whooping cough, mycoplasma pneumonia and group B strep infections.

"This is an exciting opportunity for Meridian to coordinate with Premier to place our complete illumigene molecular menu in member facilities," Mike Shaughnessy, the president of Global Diagnostics at Meridian Bioscience, said. "Meridian is privileged to collaborate with Premier to assist its alliance members in their efforts to deliver improved clinical outcomes improve operating efficiencies and reduce costs in their facilities."

Based in Raleigh, Premier serves more than 3,000 hospitals and 110,000 other healthcare sites across the country. Each Premier facility will have access to Meridian's illumigene tests, which use loop-mediated isothermal DNA amplification (LAMP) technology.

The tests are highly sensitive and provide results within an hour, thereby helping to facilitate early diagnosis and treatment of disease.